novocure Can now sell its glioblastoma therapy in Canada as well. Canadian Regulatory Authority healthcanada according to a Press realease The Lucerne-based oncology company granted the Optune approval. According to the information, more than 25 thousand patients have been treated with this in other places.

Optune is a small, wearable medical device that generates an electric field. With their physical powers, they stop the division of cancer cells. Optune is the first therapy for this most common primary and most aggressive brain tumor to be approved in Canada in 12 years.

“It is well known that the treatment of glioblastoma represents a major medical need,” said Dr. David Robert, professor of radiology, radiation oncology and nuclear medicine and president-elect of the Canadian Association of Radiation Oncology. “The approval of Optune could provide a real benefit to Canadian patients.”

Novocure Chief Commercial Officer Preesh Shah said that Novocure is now working to ensure coverage by public and private insurance companies at the earliest. “We are proud to have reached this milestone as a company and are committed to ensuring that our treatments are available to all sufferers around the world who could benefit from them.”

Novocure has been present in Canada since 2013. As recently as November, Novocure has a Montreal Office Revealed. mm